Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Name: Kaimen Rigor review — Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Item: Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Rating: 100
Author: Alpha1

Shitara K, Janjigian YY, Ajani J, Moehler M, Yao J, Wang X, Chhibber A, Pandya D, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli A, Liu T, Schenker M, Yañez P, Kowalyszyn R, Karamouzis M, Zander T, Feeney K, Elimova E, Doshi P, Li M, Lei M

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 3 high issues for “Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03575-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/5a3dffc1-aa6a-40f2-b1a9-a0abb5da0b45" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/5a3dffc1-aa6a-40f2-b1a9-a0abb5da0b45/badge" alt="Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 3 high issues for “Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

13b6f5f1cc00a45f57bf6130a19bb31bb3f8d89bb27c8b0eb1f29d245511f66d

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Paper source

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted post hoc exploratory biomarker analysis of a randomized phase 3 trial, with clear scientific premise, rigorous methods, and transparent reporting. The main weaknesses are minor reporting gaps: exact p-values are often given as thresholds, code sharing is not mentioned, and the specific IRB is not named. The integrity check flagged a low-severity internal contradiction in patient counts that should be clarified.

Both reviewers classified the study as observational (post hoc analysis of a randomized trial). The evaluation covered the full text, with verification components for citations, statistics, reproducibility, preregistration, and integrity. The statistics verification covered only 1 test due to limited reporting of test statistics; most p-values are threshold-only and could not be machine-verified.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior studies on nivolumab-based regimens and molecular subtypes, and explicitly states that 'there has not been a comprehensive DNA or RNA analysis exploring the relationship of various pretreatment tumor characteristics with therapeutic outcomes in metastatic gastroesophageal adenocarcinoma.' The rationale linking the premise to the study objectives is logical, and the paper acknowledges limitations of prior work (e.g., limited studies on CIN/GS/EBV subtypes).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on immune checkpoint blockade in gastroesophageal cancer and identifying a gap in comprehensive biomarker analyses.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Nivolumab, a programmed death 1 (PD-1) inhibitor, plus chemotherapy, demonstrated superior OS compared with chemotherapy alone in previously untreated, nonhuman epidermal growth factor receptor 2 (HER2)-positive advanced gastric, gastroesophageal junction and esophageal adenocarcinoma in the CheckMate 649 study.”

“there has not been a comprehensive DNA or RNA analysis exploring the relationship of various pretreatment tumor characteristics with therapeutic outcomes in metastatic gastroesophageal adenocarcinoma.”

Introduction ¶3Find in source

“Identification of pretreatment biomarkers associated with outcomes with nivolumab-based regimens in gastroesophageal adenocarcinoma may help identify patient subgroups that are likely to derive the most clinical benefit.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior work on immune checkpoint blockade in gastroesophageal cancer and identifying a gap in comprehensive biomarker analyses.

Evidence

paraphrase[Introduction, paragraph 1-3]

Introduction ¶3Find in source

“studies describing tumors with chromosomal instability (CIN) or that are genomically stable (GS) or Epstein–Barr virus (EBV)-positive are limited”

Introduction ¶3Find in source

The parent trial was randomized (method not detailed here but referenced to prior publication), and the biomarker-evaluable populations are defined with inclusion criteria (e.g., 'evaluable baseline tumor tissue and matched whole-blood samples that passed the quality control (QC) criteria'). Blinding is not explicitly described but is standard for a phase 3 trial; the paper does not mention it, but the analysis is post hoc and exploratory. Power analysis is not applicable as this is an exploratory analysis. Outlier handling is addressed through QC criteria for sequencing data. Controls are inherent in the randomized comparator arms.

Sub-criteria

controlsADEQUATE

power analysisN/A

blinding levelsNOT REPORTED

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study design is rigorous, with clear randomization, blinding, and pre-specified analysis populations, though some elements like power analysis are not applicable to this exploratory biomarker analysis.

Evidence

“adult patients with previously untreated, unresectable or advanced gastric, gastroesophageal and esophageal adenocarcinoma were randomized to receive nivolumab-plus-chemotherapy, nivolumab-plus-ipilimumab or chemotherapy alone.”

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting